Acasti Pharma Inc. Reports Positive Test Results (NEPT)

Acasti Pharma Inc., a subsidiary of Neptune Technologies & Bioressources Inc.

reports significant results on the effects of its anti-dyslipidemic investigational drug candidate CaPre™ on C-reactive protein levels, a biomarker of CardioVascular Disease risk and associated with diabetes and obesity. Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets.